Charcot-Marie-Tooth neuropathies: Diagnosis and management

Seminars in Neurology

Volumn 28, Issue 2, 2008, Pages 185-194

  Jani Acsadi, Agnes ^a   Krajewski, Karen ^a   Shy, Michael E ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Charcot Marie Tooth disease; Diagnosis; Heterogeneity; Treatment

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ASCORBIC ACID; CARBAMAZEPINE; DESIPRAMINE; GABAPENTIN; IMMUNOMODULATING AGENT; LAMOTRIGINE; LIDOCAINE; NORTRIPTYLINE; ONAPRISTONE; PREGABALIN; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG MEGADOSE; ELECTROPHYSIOLOGY; GENE THERAPY; GENOTYPE PHENOTYPE CORRELATION; HEREDITARY MOTOR SENSORY NEUROPATHY; HISTORY; HUMAN; INHERITANCE; MORBIDITY; MUSCLE ATROPHY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT PLANNING; WEAKNESS;

ANIMALS; CHARCOT-MARIE-TOOTH DISEASE; DIAGNOSIS, DIFFERENTIAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, ANIMAL; MUTATION; PAIN; PATIENT EDUCATION AS TOPIC; PERIPHERAL NERVES;

EID: 41149085223     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1062264     Document Type: Review

References (54)

1. Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet 1974;6:98-118
2. Shy M, Lupski JR, Chance PF, Klein CJ, Dyck P. The hereditary motor and sensory neuropathies: an overview of the clinical, genetic, electrophysiologic and pathologic features. In: Dyck PJ, ed. Peripheral Neuropathy. 4th ed. Philadelphia: WB Saunders; 2005:1623-1658
3. Song SJ, Zhang YZ, Chen B, et al. No mutation was detected in the LMNA gene among sporadic Charcot-Marie-Tooth patients. Beijing Da Xue Xue Bao 2006;38:78-79
4. Charcot J, Marie P. Sue une forme particulaire d'atrophie musculaire progressive souvent familial debutant par les pieds et les jamber et atteingnant plus tard les mains. Re Med 1886;6:97-138
5. Tooth H. The Peroneal Type of Progressive Muscular Atrophy. London: Lewis; 1886
6. Dejerine H, Sottas J. Sur la nevritte interstitielle, hypertrophique et progressive de l'enfance. CR Soc Biol Paris 1893;45:63-96
7. Roussy G, Levy G. A sept cas d'une maladie familiale particulaire. Rev Neurol 1926;33:427-450
8. Dawidenkow S. Über die neurotische Muskelatrophie Charcot-Marie: Klinisch-genetische Studien. Z Ges Neurol Psychiat 1927;107:259
9. Dawidenkow S. Über dir neurotische Muskelatrophie Charcot-Marie: Klinisch-genetische Studien. Z Neurol 1927; 108:344
10. Dyck PJ, Lambert EH. Lower motor and primary sensory neuron diseases with peroneal muscular atrophy: II. Neurologic, genetic, and electrophysiologic findings in various neuronal degenerations. Arch Neurol 1968;18:619-625
11. Dyck PJ, Lambert EH. Lower motor and primary sensory neuron diseases with peroneal muscular atrophy: I. Neurologic, genetic, and electrophysiologic findings in hereditary polyneuropathies. Arch Neurol 1968;18:603-618
12. Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain 1980;103: 259-280
13. Harding AE, Thomas PK. Genetic aspects of hereditary motor and sensory neuropathy (types I and II). J Med Genet 1980;17:329-336
14. Aguayo AJ, Attiwell M, Trecarten J, Perkins S, Bray GM. Abnormal myelination in transplanted Trembler mouse Schwann cells. Nature 1977;265:73-75
15. Aguayo AJ, Kasarjian J, Skamene E, Kongshavn P, Bray GM. Myelination of mouse axons by Schwann cells transplanted from normal and abnormal human nerves. Nature 1977;268:753-755
16. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 1991;66:219-232
17. Raeymaekers P, Timmerman V, Nelis E, et al. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT1a). The HMSN Collaborative Research Group. Neuromuscul Disord 1991;1:93-97
18. Shy ME, Jani A, Krajewski KM, et al. Phenotypic clustering in MPZ mutations. Brain 2004;127:371-384
19. Bradley WG, Madrid R, Davis CJ. The peroneal muscular atrophy syndrome. Clinical, genetic, electrophysiological and nerve biopsy studies. Part 3: Clinical, electrophysiological and pathological correlations. J Neurol Sci 1977;32: 123-136
20. Lovelace R. Hereditary induced peripheral neuropathies. Clin Podiatr Med Surg 1990;7:37-50
21. Nicholson G, Nash J. Intermediate nerve conduction velocities define X-linked Charcot-Marie-Tooth neuropathy families. Neurology 1993;43:2558-2564
22. Nelis E, Van Broeckhoven C, De Jonghe P, et al. Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet 1996;4:25-33
23. Shy ME, Scavina MT, Clark A, et al. T118M PMP22 mutation causes partial loss of function and HNPP-like neuropathy. Ann Neurol 2006;59:358-364
24. Dyck PJ, Oviatt KF, Lambert EH. Intensive evaluation of unclassified neuropathies yields improved diagnosis. Ann Neurol 1981;10:222-226
25. Ionasescu W, Burns TL, Searby C, Ionasescu R. X-linked dominant Charcot-Marie-Tooth neuropathy with 15 cases in a family genetic linkage study. Muscle Nerve 1988;11:1154-1156
26. Wise CA, Garcia CA, Davis SN, et al. Molecular analyses of unrelated Charcot-Marie-Tooth (CMT) disease patients suggest a high frequency of the CMTIA duplication. Am J Hum Genet 1993;53:853-863
27. Li J, Krajewski K, Lewis RA, Shy ME. Loss-of-function phenotype of hereditary neuropathy with liability to pressure palsies. Muscle Nerve 2004;29:205-210
28. Nicholson GA. Mutation testing in Charcot-Marie-Tooth neuropathy. Ann N Y Acad Sci 1999;883:383-388
29. Ionasescu W, Ionasescu R, Searby C. Screening of dominantly inherited Charcot-Marie-Tooth neuropathies. Muscle Nerve 1993;16:1232-1238
30. Shy ME. Therapeutic strategies for the inherited neuropathies. Neuromolecular Med 2006;8:255-278
31. Suter U, Scherer SS. Disease mechanisms in inherited neuropathies. Nat Rev Neurosci 2003;4:714-726
32. Arroyo EJ, Scherer SS. On the molecular architecture of myelinated fibers. Histochem Cell Biol 2000;113:1-18
33. Massicotte C, Scherer SS. Neuropathies: translating causes into treatments. In: Waxman SG, ed. Neuroscience, Molecular Medicine, and the Therapeutic Transformation of Neurology. Philadelphia: Elsevier Science; 2004:405-418
34. Kamholz J, Menichella D, Jani A, et al. Charcot-Marie-Tooth disease type 1: molecular pathogenesis to gene therapy. Brain 2000;123:222-233
35. Wrabetz L, Feltri ML, Kleopa K. Inherited neuropathies: clinical, genetic, and biological features. In: Lazzarini RA, ed. Myelin Biology and Disorders. London: Elsevier; 2004: 905-952
36. Michailov GV, Sereda MW, Brinkmann BG, et al. Axonal neuregulin-1 regulates myelin sheath thickness. Science 2004;304:700-703
37. Taveggia C, Zanazzi G, Petrylak A, et al. Neuregulin-1 type III determines the ensheathment fate of axons. Neuron 2005-47:681-694
38. Lewis RA, Sumner AJ, Shy ME. Electrophysiological features of inherited demyelinating neuropathies: a reappraisal in the era of molecular diagnosis. Muscle Nerve 2000; 23:1472-1487
39. Brust JC, Lovelace RE, Devi S. Clinical and electrodiagnostic features of Charcot-Marie-Tooth syndrome. Acta Neurol Scand Suppl 1978;68:1-142
40. Davis CJF, Bradley WG, Madrid R. The peroneal muscular atrophy syndrome: clinical, genetic, electrophysiological and nerve biopsy findings and classification. J Genet Hum 1978; 26:311-349
41. Krajewski KM, Lewis RA, Fuerst DR, et al. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 2000;123:1516-1527
42. Shy ME, Rose MR. Charcot-Marie-Tooth disease impairs quality of life: why? And how do we improve it? Neurology 2005;65:790-791
43. Arnold LD, Bachmann GA, Rosen R, Kelly S, Rhoads GG. Vulvodynia: characteristics and associations with comorbidities and quality of life. Obstet Gynecol 2006;107:617-624
44. Vinci P, Serrao M, Millul A, et al. Quality of life in patients with Charcot-Marie-Tooth disease. Neurology 2005;65:922-924
45. Carter GT, Han JJ, Abresch RT, Jensen MP. The importance of assessing quality of life in patients with neuromuscular disorders. Am J Hosp Palliat Care 2006;23: 493-497
46. Krajewski KM, Shy ME. Genetic testing in neuromuscular disease. Neurol Clin 2004;22:481-508
47. Bird TD. Risks and benefits of DNA testing for neurogenetic disorders. Semin Neurol 1999;19:253-259
48. Boerkoel CF, Takashima H, Garcia CA, et al. Charcot-Marie-Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation. Ann Neurol 2002;51:190-201
49. Sereda M, Griffiths I, Puhlhofer A, et al. A transgenic rat model of Charcot-Marie-Tooth disease. Neuron 1996;16: 1049-1060
50. Guenard V, Schweitzer B, Flechsig E, et al. Effective gene transfer of lacZ and P0 into Schwann cells of P0-deficient mice. Glia 1999;25:165-178
51. lanokova E, Lewis R, Acsadi G, et al. AAV-GDNF improves neuropathy in MPZ-/- mice. Neurology 2006;66 (suppl 2):A276
52. Maurer M, Kobsar I, Berghoff M, Schmid CD, Carenini S, Martini R. Role of immune cells in animal models for inherited neuropathies: facts and visions. J Anat 2002;200: 405-414
53. Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004;10:396-401
54. Sereda MW, Meyer Zu Horste G, Suter U, Uzma N, Nave KA. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003;9:1533-1537